Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

PALO ALTO, Calif., March 7, 2011 /PRNewswire/ --Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2010.

Total revenues for the fourth quarter of 2010 were $53.4 million, compared to $38.3 million for the fourth quarter of 2009.  Full year 2010 revenues were $173.8 million, up 35 percent compared to revenues of $128.4 million for 2009.  

GAAP net income for the fourth quarter of 2010 was $24.5 million, or $0.56 per diluted share, compared to $5.7 million, or $0.17 per diluted share, for the fourth quarter of 2009.  GAAP net income for 2010 was $32.8 million, or $0.83 per diluted share, compared to a 2009 GAAP net loss of $6.8 million, or $0.23 per diluted share.

Adjusted net income for the fourth quarter of 2010 was $27.2 million, or $0.63 per diluted share, compared to $10.8 million, or $0.33 per diluted share, for the fourth quarter of 2009.  Adjusted net income for 2010 was $61.0 million, or $1.55 per diluted share, compared to a 2009 adjusted net loss of $1.5 million, or $0.05 per diluted share.  A reconciliation of GAAP net income (loss) to adjusted net income (loss) and the related per diluted share amounts is included with this press release.

Net sales of Xyrem® (sodium oxybate) oral solution increased 36 percent to $42.9 million for the fourth quarter of 2010, compared to net sales of $31.6 million for the fourth quarter of 2009.  Xyrem net sales for 2010 increased 47 percent to $142.6 million, compared to $96.8 million in net sales for 2009.  Net sales of once-daily Luvox CR® (fluvoxamine maleate) increased to $9.4 million for the fourth quarter of 2010, compared to $5.7 million for the fourth quarter of 2009.  Luvox CR net sales for 2010 increased to $27.4 million, compared to 2009 net sales of $18.3 million.  Both fourth quarter and full year 2010 net sales of Luvox CR include $2.0 million of revenue recorded as a result of a change in the timing of when revenue is recognized; the company now records Luvox CR sales upon shipment to distributors net of estimated returns.  The profit associated with this change has been excluded from the company's fourth quarter and full year 2010 adjusted net income.

"In 2010, our first full year of profitability, our progress included strengthening our balance sheet, enhancing our commercial business management team, significantly increasing Xyrem sales, and broadening our patent protection for sodium oxybate," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "We look forward to improving our performance in 2011, as we continue to grow and protect our Xyrem business and advance our intranasal clonazepam product candidate for acute repetitive seizures in epilepsy patients."

Research and development expenses for the fourth quarter of 2010 were $4.1 million, compared to $6.3 million for the fourth quarter of 2009.  Research and development expenses in 2010 were $25.6 million, compared to $36.6 million for 2009.  

Selling, general and administrative expenses for the fourth quarter of 2010 were $17.1 million, compared to $15.7 million for the fourth quarter of 2009.  In 2010, selling, general and administrative expenses were $69.0 million, compared to $58.7 million for 2009.

Interest expense for the fourth quarter of 2010 was $1.1 million, compared to $5.8 million for the prior year period.  Interest expense in 2010 was $12.7 million, compared to $22.8 million in 2009.  As of December 31, 2010, cash and cash equivalents were $44.8 million, an increase from $22.9 million at September 30, 2010.

2011 Financial GuidanceJazz Pharmaceuticals is providing full year 2011 financial guidance as follows:-- Total product sales

$ 232 - 245 million -- Xyrem

$ 200 – 210 million-- Luvox CR

$ 32 – 35 million-- Gross margin

greater than 90%-- R&D expenses

$ 20 – 24 million-- SG&A expenses

$ 87 - 93 million-- GAAP net income per diluted share

$ 2.22 – 2.41-- Adjusted net income per diluted share*

$ 2.70 – 2.90 *  A reconciliation of GAAP net income to adjusted net income and the related per diluted share amounts is available in a table with this press release.Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 1:30 p.m. PT/4:30 p.m. ET to provide a business update and discuss 2010 financial results and 2011 financial guidance.  The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.JazzPharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.  Investors may participate in the conference call by dialing 1-866-362-4829 in the U.S., or 1-617-597-5346 outside the U.S., and entering passcode 60782035.

An archived version of the webcast will be available for at least one week on the investors section of the Jazz Pharmaceuticals' website at www.JazzPharmaceuticals.com.

About Jazz Pharmaceuticals, Inc.Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.  For further information see www.JazzPharmaceuticals.com.

Non-GAAP Financial MeasuresTo supplement our financial results and financial guidance presented on a GAAP basis, we use the non-GAAP measures adjusted net income/(loss) and adjusted net income/(loss) per diluted share.  We believe these non-GAAP financial measures are helpful in understanding our past financial performance and our potential future results.  They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP.  Our management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions.  Compensation of our executives is based in part on the performance of our business based on these non-GAAP measures.  In addition, we believe that the use of these non-GAAP measures enhances the ability of investors to compare our results from period to period.  Investors should note that adjusted net income/(loss) and adjusted net income/(loss) per diluted share, as used by Jazz Pharmaceuticals, may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by our competitors and other companies.  Adjusted net income/(loss) and adjusted net income/(loss) per diluted share exclude from the comparable GAAP measures:  revenue related to upfront and milestone payments, the impact of a change in the timing of when Luvox CR revenue is recognized, a loss on extinguishment of debt, amortization of intangible assets, stock-based compensation, and non-cash interest expense associated with a debt discount and debt issuance costs.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' financial performance, profitability and growth potential and future financial performance, including 2011 financial guidance, and statements relating to future product sales and product candidate development.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' dependence on sales of Xyrem, and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; the uncertain and time-consuming clinical development and regulatory process for its product candidates, including its intranasal clonazepam product candidate; regulatory risks; Jazz Pharmaceuticals' cash flow estimates, the sufficiency of its cash resources; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its quarterly report on Form 10-Q for the quarter ended September 30, 2010 filed with the Securities and Exchange Commission on November 5, 2010.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009 Revenues: Product sales, net

$
52,357$
37,319$ 170,006$ 115,108 Royalties, net

7286812,6372,203 Contract revenues

2842841,13811,138 Total revenues

53,36938,284173,781128,449 Operating expenses: Cost of product sales

4,7842,78213,5599,638 Research and development

4,1186,31725,61236,561 Selling, general and administrative

17,07015,71868,99658,652 Intangible asset amortization

1,8622,0577,8257,668 Total operating expenses

27,83426,874115,992112,519 Income from operations

25,53511,41057,78915,930 Interest income

15634 Interest expense

(1,077)(5,762)(12,728)(22,796) Other expense

--(2)(4) Loss on extinguishment of debt

--(12,287)- Net income (loss)

$
24,459$
5,653$   32,778$   (6,836) Net income (loss) per share: Basic

$
.62$
.18$
.90$
(0.23) Diluted

$
.56$
.17$
.83$
(0.23) Weighted-average common shares used in computing   net income (loss) per share: Basic

39,45631,15536,34330,018 Diluted

43,40533,30539,41130,018JAZZ PHARMACEUTICALS, INC.SUMMARY OF PRODUCT SALES, NET(In thousands)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009Xyrem

$
42,931$
31,644$ 142,630$   96,763Luvox CR

9,4265,67527,37618,345Total

$
52,357$
37,319$ 170,006$ 115,108JAZZ PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)December 31,December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$
44,794$
5,595Restricted cash

4002,988Accounts receivable, net of allowances

22,08112,313Inventories

5,0463,426Prepaid expenses

1,8581,653Other current assets

279979Total current assets

74,45836,954Property and equipment, net

6901,124Intangible assets, net

22,03329,858Goodwill

38,21338,213Other long-term assets

3351,247Total assets

$
35,729$
7,396LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current liabilities:Revolving credit facility

$
7,350$
9,399Accounts payable

3,0492,158Accrued liabilities

23,57214,296Current portion of long-term debt

16,06423,759Purchased product rights liability

4,5004,000Liability under government settlement

4,1282,954Deferred revenue

1,2732,675Total current liabilities

59,93659,241Deferred rent

8229Deferred revenue, non-current

9,05310,191Purchased product rights liability, non-current

4,5009,000Liability under government settlement, non-current

6,97810,658Long-term debt, less current portion

24,62991,107Total stockholders' equity (deficit)

30,551(72,830)Total liabilities and stockholders' equity (deficit)

$
35,729$
7,396JAZZ PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(In thousands, except per share amounts)(Unaudited)Three Months Ended December 31,Year Ended December 31,2010200920102009 GAAP net income (loss)

$
24,459$
5,653$   32,778$   (6,836) Add: Intangible asset amortization

1,8622,0577,8257,668 Stock-based compensation expense

2,2502,4488,2195,957 Non-cash interest expense

2319612,4062,810 Loss on extinguishment of debt

--12,287- Deduct: Contract revenues

(284)(284)(1,138)(11,138) Luvox CR revenue recognition timing change

(1,345)-(1,345)- Adjusted net income (loss)

$
27,173$
,835$   61,032$   (1,539) GAAP net income (loss) per diluted share

$
.56$
.17$
.83$
(0.23) Adjusted net income (loss) per diluted share

$
.63$
.33$
.55$
(0.05) Shares used in computing GAAP and adjusted net income (loss) per diluted share amounts

43,40533,30539,41130,018JAZZ PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP 2011 FINANCIAL GUIDANCE(In millions, except per share amounts) GAAP net income

$100-110 Add: Intangible asset amortization

7 Stock-based compensation expense

15-16 Non-cash interest expense

1 Deduct: Contract revenues

(1) Adjusted net income

$122-132 GAAP net income per diluted share

$2.22-2.41 Adjusted net income per diluted share

$2.70-2.90 Shares used in computing GAAP and adjusted net income per diluted share amounts

45-46
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ... into a settlement agreement with the United States ... SEC,s investigation into possible violations of the Foreign ... the settlement agreement, SciClone has agreed to pay ... interest and a penalty.  This payment is in ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... In sleep, when the defenses of the day are at rest, ... with eating disorders is significant self-criticism, and consequently these patients experience this disease with ... maladaptive means for coping with this unease, but also leads to a reservoir of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... practical mobile kitchens, recently announced the debut of their latest mobile kitchen model, ... Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in the ...
(Date:2/5/2016)... Moscow, Russia (PRWEB) , ... February 05, 2016 , ... ... update has a completely new user interface design and the developer has fixed known ... with those they want to on their phone while not consuming any of their ...
(Date:2/5/2016)... ... , ... –This week, Atascadero water heater company First Call Plumbing ... view the report, click here or see below. , There are ... and cons, the type chosen is almost entirely up to personal preference. However, tankless ...
(Date:2/5/2016)... ... ... tired of trying to cram belongings into spare space that just isn’t there, a self-storage ... before hastily spending money on a unit, take these tips into consideration. , Self-storage is ... often not told when utilizing these services are some tips on how to use the ...
Breaking Medicine News(10 mins):